. . . . "1698"^^ . . . . . "\u0644\u064A\u0631\u064A\u0644\u0648\u0645\u0627\u0628 \u062C\u0633\u0645 \u0645\u0636\u0627\u062F \u0648\u062D\u064A\u062F \u0627\u0644\u0646\u0633\u064A\u0644\u0629 \u0628\u0634\u0631\u064A \u0637\u0648\u0631\u062A\u0647 \u0628\u0631\u064A\u0633\u062A\u0648\u0644 \u0645\u0627\u064A\u0631\u0632 \u0633\u0643\u0648\u064A\u0628 \u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0633\u0631\u0637\u0627\u0646."@ar . . . . . "S9XDI9W918"@en . . "Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb."@en . "1000676"^^ . . . . . "\u0644\u064A\u0631\u064A\u0644\u0648\u0645\u0627\u0628 \u062C\u0633\u0645 \u0645\u0636\u0627\u062F \u0648\u062D\u064A\u062F \u0627\u0644\u0646\u0633\u064A\u0644\u0629 \u0628\u0634\u0631\u064A \u0637\u0648\u0631\u062A\u0647 \u0628\u0631\u064A\u0633\u062A\u0648\u0644 \u0645\u0627\u064A\u0631\u0632 \u0633\u0643\u0648\u064A\u0628 \u0644\u0639\u0644\u0627\u062C \u0627\u0644\u0633\u0631\u0637\u0627\u0646."@ar . "none"@en . . "Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3. This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb."@en . "1092789530"^^ . . . "D10444" . "3544"^^ . "mab"@en . . . . "Lirilumab"@en . . . "6452"^^ . . "mab"@en . . . . . . . . "u"@en . . . "none"@en . "\u0644\u064A\u0631\u064A\u0644\u0648\u0645\u0627\u0628"@ar . "1000676-41-4" . . . "2030"^^ . . "S9XDI9W918" . "38166296"^^ . . "9918"^^ . . . . . . . . "D10444"@en . . . . . "46"^^ .